Search

Your search keyword '"Urun, Yuksel"' showing total 171 results
Start Over Author "Urun, Yuksel"
171 results on '"Urun, Yuksel"'

3. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

Author

Yasar, Hatime Arzu, Aktas, Burak Yasin, Ucar, Gokhan, Goksu, Sema Sezgin, Bilgetekin, Irem, Cakar, Burcu, Sakin, Abdullah, Ates, Ozturk, Basoglu, Tugba, Arslan, Cagatay, Demiray, Atike Gokcen, Paydas, Semra, Cicin, Irfan, Sendur, Mehmet Ali Nahit, Karadurmus, Nuri, Kosku, Hakan, Uner, Aytuğ, Yumuk, Perran Fulden, Utkan, Gungor, Kefeli, Umut, Tanriverdi, Ozgur, Cinkir, Havva, Gumusay, Ozge, Turhal, Nazım Serdal, Menekse, Serkan, Kut, Engin, Beypinar, Ismail, Sakalar, Teoman, Demir, Hacer, Yekeduz, Emre, Kilickap, Saadettin, Erman, Mustafa, and Urun, Yuksel

Published
2024
Full Text
View/download PDF

4. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.

Author

Karadurmus, Nuri, Kaplan, Muhammet Ali, Sendur, Mehmet Ali Nahit, Urun, Yuksel, Demirci, Umut, Karaca, Saziye Burcak, Goktas Aydin, Sabin, Aykan, Musa Baris, Bilici, Ahmet, Sezer, Ahmet, Yilmaz, Ulku, Abali, Huseyin, Yumuk, Perran Fulden, Degirmencioglu, Serkan, Demirkazik, Ahmet, Paydas, Semra, Mirili, Cem, Turna, Hande, Kargi, Aysegul, and Ozdogan, Mustafa

Subjects
NON-small-cell lung carcinoma, NIVOLUMAB, CANCER fatigue, ADVERSE health care events
Abstract

To evaluate the efficacy and safety of nivolumab in the second-line (2L) or later-line (LL) treatment of patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) in real-life setting in Türkiye. This study was designed as a national, multi-center, retrospective study. The study population was evaluated in two groups for the line of nivolumab therapy: those receiving nivolumab in the 2L (Group 2L) and third-line (3L) or LL (Group 3L/LL). Efficacy was evaluated based on one-year overall survival (OS) and progression-free survival (PFS). Safety was evaluated based on treatment-related adverse events (AEs) and nivolumab discontinuation rate. Of 244 patients, 52.9% were in Group 2L and 47.1% were in Group 3L/LL. Demographic and clinical characteristics did not differ between the groups. In Group 2L and Group 3L/LL, one-year OS and PFS rates were 60.8% and 61.4% (p = 0.592) and 31.2% and 21.3% (p = 0.078), respectively. The objective response rate (ORR) was 34.7% in Group 2L and 27.3% in Group 3L/LL (p = 0.262). The percentage of patients reporting at least one AE in Groups 2L and 3L/LL was 34.9% and 43.5%, respectively (p = 0.169). Fatigue was the most common (16.4%) treatment-related AE in each group. The groups were comparable regarding the AE frequency. Nivolumab was discontinued in 61 patients in Group 2L and 53 patients in Group 3L/LL, with the most common reason being disease progression (57.4% and 66.0%, respectively). Nivolumab is safe and effective in the 2L or 3L/LL treatment of locally advanced/metastatic NSCLC and associated with acceptable AEs in real-life setting. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (around 85% of all lung cancers). Patients with NSCLC are usually diagnosed at advanced or metastatic stages. When cancer cells spread to other areas from where they first formed, it is called metastatic cancer. Surgery may not be a treatment option for such patients. Currently, immunotherapeutic agents are used in the treatment of NSCLC. Nivolumab is one of the approved immunotherapeutic agents in the treatment of patients with metastatic NSCLC, who have failed after receiving chemotherapy. Our study explored the efficacy and safety of nivolumab in real-life setting in Türkiye. Nivolumab effectiveness was evaluated by overall survival (OS) and progression-free survival (PFS) rates. OS indicates the proportion of patients who are still alive at a given time after diagnosis or treatment initiation. PFS refers to "the length of time during and after cancer treatment that a person lives with the disease but does not get worse." In the present study, one-year OS for 244 patients who received nivolumab was 61.1% and one-year PFS was 26.4%. Nivolumab safety was evaluated based on the frequency of adverse events observed during nivolumab therapy. Of the patients 38.9% had at least one side effect, with fatigue being the most common (16.4%). Our results support the earlier studies and showed that nivolumab was a safe and effective agent and is associated with acceptable side effects. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, and Powles, Thomas

Published
2020
Full Text
View/download PDF

8. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Author

Guven, Deniz Can, primary, Aykan, Musa Baris, additional, Muglu, Harun, additional, Bayram, Ertugrul, additional, Helvaci, Kaan, additional, Dursun, Bengü, additional, Celayir, Melisa, additional, Chelebiyev, Elvin, additional, Nayir, Erdinc, additional, Erman, Mustafa, additional, Sezer, Ahmet, additional, Urun, Yuksel, additional, Demirci, Umut, additional, Er, Ozlem, additional, Disel, Umut, additional, Bilici, Ahmet, additional, Arslan, Cagatay, additional, Karadurmus, Nuri, additional, and Kilickap, Saadettin, additional

Published
2023
Full Text
View/download PDF

10. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study.

Author

Guven, Deniz Can, Aykan, Musa Baris, Muglu, Harun, Bayram, Ertugrul, Helvaci, Kaan, Dursun, Bengü, Celayir, Melisa, Chelebiyev, Elvin, Nayir, Erdinc, Erman, Mustafa, Sezer, Ahmet, Urun, Yuksel, Demirci, Umut, Er, Ozlem, Disel, Umut, Bilici, Ahmet, Arslan, Cagatay, Karadurmus, Nuri, and Kilickap, Saadettin

Subjects
IMMUNE checkpoint inhibitors, MERKEL cell carcinoma, IMMUNOTHERAPY, COMBINATION drug therapy, PROGRESSION-free survival, GERM cell tumors
Abstract

Introduction: The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi-center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT) in patients with advanced rare tumors. Methods: In this retrospective cohort study, we included 93 patients treated with ICIs for NCI-defined rare tumors from the 12 cancer centers in Turkey. The primary endpoints were the overall response (ORR) and disease control rate (DCR). Results: The cohort's median age was 56, and 53.8% of the patients were male. The most frequent diagnosis was sarcoma (29%), and 81.7% of the patients were previously treated with at least one line of systemic therapy in the advanced stage. The ORR and DCR were 36.8% and 63.2%, respectively. The germ cell tumors had the lowest ORR (0%), while the Merkel cell carcinoma had the highest ORR to ICIs (57.1%). Patients treated with ICI+ICI or ICI plus chemotherapy combinations had higher ORR (55.2% vs. 27.6%, p=0.012) and DCR (82.8% vs. 53.4%, p=0.008). The median OS was 13.47 (95% CI: 7.79–19.15) months, and the six and 12- month survival rates were 71% and 52%. The median duration of response was 16.59months, and the 12-month progression-free survival rate was 66% in responders. The median time-to-treatment failure was 5.06months (95% CI: 3.42– 6.71). Three patients had high-grade irAEs with ICIs (grade 3 colitis, grade 3 gastritis, and grade 3 encephalitis in one patient each). Conclusion: We observed over 30% ORR and a 13-month median OS in patients with rare cancers treated with ICI monotherapy or ICI plus CT combinations. The response rates to ICIs or ICIs plus CT significantly varied across different tumor types. Responding patients had over 2 years of survival, highlighting a need for further trials with ICIs for patients with rare tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, Vaishampayan, Ulka, Petrylak, Daniel P, Chi, Kim N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Yu, Evan Y, Géczi, Lajos, Hegemann, Miriam, Percent, Ivor J, Tucci, Marcello, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, and Bell-McGuinn, Katherine M

Published
2017
Full Text
View/download PDF

14. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Author

Goktas Aydin, Sabin, primary, Kavak, Engin Eren, additional, Topcu, Atakan, additional, Bayramgil, Ayberk, additional, Akgul, Fahri, additional, Kahraman, Seda, additional, Aykan, Musa Baris, additional, Altıntas, Yunus Emre, additional, Helvaci, Kaan, additional, Urun, Yuksel, additional, Bilici, Ahmet, additional, Seker, Mesut, additional, Sendur, Mehmet Ali Nahit, additional, Olmez, Omer Fatih, additional, Acikgoz, Ozgur, additional, and Cicin, Irfan, additional

Published
2023
Full Text
View/download PDF

15. Major and minor salivary gland cancers: A multicenter retrospective study

Author

Hacioglu, Muhammet Bekir, primary, Erdogan, Bulent, additional, Bardakcı, Murat, additional, Algın, Efnan, additional, Gulbagcı, Burcu, additional, Hacibekiroglu, Ilhan, additional, Hamdard, Jamshid, additional, Olmez, Omer Fatih, additional, Akkus, Hadi, additional, Oksuzoglu, Berna, additional, Goksu, Sema Sezgin, additional, Dae, Shute Ailia, additional, Sumbul, Ahmet Taner, additional, Ugraklı, Muzaffer, additional, Karaagac, Mustafa, additional, Sahin, Elif, additional, Cabuk, Devrim, additional, Ozer, Ozden, additional, Yavuzsen, Tugba, additional, Arıkan, Rukiye, additional, Köstek, Osman, additional, Atcı, Muhammed Mustafa, additional, Sakin, Abdullah, additional, Deligonul, Adem, additional, Bayır, Duygu, additional, Dincer, Murat, additional, Unsal, Oktay, additional, Yazıcı, Ozan, additional, Zeynelgil, Esra, additional, Gulmez, Ahmet, additional, Harputluoglu, Hakan, additional, Erol, Cihan, additional, Sendur, Mehmet Ali Nahit, additional, Aytekin, Aydin, additional, Akagunduz, Baran, additional, Oner, Irem, additional, Er, Ozlem, additional, Oztosun, Bugra, additional, Gumus, Mahmut, additional, Biricik, Fatih Selcuk, additional, Aykan, Musa Baris, additional, Karadurmus, Nuri, additional, Degerli, Ezgi, additional, Demirci, Nebi Serkan, additional, Turkmen, Esma, additional, Şakalar, Teoman, additional, Secmeler, Saban, additional, Tanrıverdi, Ozgur, additional, Alkan, Ali, additional, Kemal, Yasemin, additional, Cil, Ibrahim, additional, Unal, Caglar, additional, Iriagaç, Yakup, additional, Alan, Ozkan, additional, Balli, Sevinc, additional, Urun, Yuksel, additional, Ozcan, Erkan, additional, Turhal, Nazım Serdar, additional, and Cicin, Irfan, additional

Published
2023
Full Text
View/download PDF

19. Merkel cell carcinoma in Turkey: A multicentric study

Author

Yildiz, Fatih, Demirci, Umut, Küçükarda, Ahmet, Büyüksimsek, Mahmut, Sakalar, Teoman, Topcu, Turkan, Aslan, Ferit, Tufan, Gulnihal, Aydin, Ovgu, Turna, Hande, Babacan, Nalan, Basoglu, Tugba, Kurt, Bediz, Yildiz, Birol, Eren, TüLay, Demiray, Atike, Gumusay, Ozge, Arslan, Cagatay, Özdemir, Nuriye, Urun, Yuksel, Baykara, Meltem, Turan, Nedim, Uysal, Mukremin, Bilici, Ahmet, Kavgaci, Halil, Çiçin, Irfan, Kilickap, Saadettin, and Paydas, Semra

Subjects
Merkel cell carcinoma -- Statistics -- Care and treatment -- Patient outcomes, Health
Abstract

Byline: Fatih. Yildiz, Umut. Demirci, Ahmet. Küçükarda, Mahmut. Büyüksimsek, Teoman. Sakalar, Turkan. Topcu, Ferit. Aslan, Gulnihal. Tufan, Ovgu. Aydin, Hande. Turna, Nalan. Babacan, Tugba. Basoglu, Bediz. Kurt, Birol. Yildiz, Tülay. [...]

Published
2021

20. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Author

Goktas Aydin, Sabin, primary, Cakan Demirel, Burcin, additional, Bilici, Ahmet, additional, Topcu, Atakan, additional, Aykan, Musa Barış, additional, Kahraman, Seda, additional, Akbıyık, Ilgın, additional, Atci, Muhammed Mustafa, additional, Olmez, Omer Fatih, additional, Yaren, Arzu, additional, Sendur, Mehmet Ali Nahit, additional, Geredeli, Caglayan, additional, Seker, Mesut, additional, Urun, Yuksel, additional, Karadurmus, Nuri, additional, and Aydin, Ahmet, additional

Published
2022
Full Text
View/download PDF

23. Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG)

Author

Alkan, Ali, Guc, Zeynep Gulsum, Senler, Filiz Cay, Yavuzsen, Tugba, Onur, Handan, Dogan, Mutlu, Karci, Ebru, Yasar, Arzu, Koksoy, Elif Berna, Tanriverdi, Ozgur, Turhal, Serdar, Urun, Yuksel, Ozkan, Asiye, Mizrak, Dilsa, and Akbulut, Hakan

Published
2016
Full Text
View/download PDF

25. Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors

Author

Yekeduz, Emre, Trapani, Dario, Xu, Wenxin, de Vries, Elisabeth G. E., Labaki, Chris, Gyawali, Bishal, Gulati, Shuchi, Nabhan, Chadi, Utkan, Gungor, Curigliano, Giuseppe, Choueiri, Toni K., Urun, Yuksel, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
clinical trials, REPRESENTATION, PARTICIPATION, underrepresented patients, CHEMOTHERAPY, CLINICAL-TRIALS, diversity
Abstract

Our study aimed to assess inequities in the clinical trial participation for the selected patient groups. We searched the Food and Drug Administration (FDA) database and extracted phase-III clinical trial data from MEDLINE for each approved drug by the FDA between January 1, 2006, and June 30, 2020. We analyzed the inclusion/exclusion criteria, participation according to gender, ethnic group, performance score, the positivity of HBV and HCV, and HIV, having comorbidities and brain metastasis. We compared the findings with that of the general population by retrieving data from the Surveillance, Epidemiology and End Results (SEER) database. We identified 142 phase III pivotal oncology trials that enrolled 105 397 patients. The proportion of female patients in trials was lower than their relative prevalence in the general population from SEER region (36% vs 49.6%, P < .001). The rates of black patients included were lower than their relative prevalence from SEER region (2.1% vs 9.8%, P < .001). 1.3% and 0.8% of patients had HBV and HCV infections, respectively. The patients' numbers with organ dysfunction were not established due to insufficient data from clinical trials. 1.6% of all patients had controlled brain metastasis. Black patients, women and patients with brain metastasis or with HBV and HCV were underrepresented. Our study underscores the importance of expanding the inclusion/exclusion criteria of pivotal oncology trials to be more representative of patients seen in clinical practice.

Published
2021

26. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

Author

Guven, Deniz Can, primary, Acar, Ramazan, additional, Yekeduz, Emre, additional, Bilgetekin, Irem, additional, Baytemur, Naziyet Kose, additional, Erol, Cihan, additional, Ceylan, Furkan, additional, Sendur, Mehmet Ali, additional, Demirci, Umut, additional, Urun, Yuksel, additional, Karadurmus, Nuri, additional, Erman, Mustafa, additional, and Kilickap, Saadettin, additional

Published
2021
Full Text
View/download PDF

27. Management of metastatic castration-resistant prostate cancer in Middle East African countries: Challenges and strategic recommendations.

Author

Bazarbashi, Shouki, Alsharm, Abdullah, Meshref, Alaa, Mrabti, Hind, Ansari, Jawaher, Ghosn, Marwan, Abdulla, Mohamed, and Urun, Yuksel

Subjects
CASTRATION-resistant prostate cancer, GENETIC testing, PROSTATE cancer
Abstract

Despite the reliance on Western guidelines for managing prostate cancer (PC), there are wide variations and gaps in treatment among developing countries such as the Middle East African (MEA) region. A multidisciplinary team of experts from the MEA region engaged in a comprehensive discussion to identify the real-world challenges in diagnostics and treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) and provided insights on the urgent unmet needs. We present a consensus document on the region-specific barriers, key priority areas and strategic recommendations by experts for optimizing management of mCRPC in the MEA. Limited access to genetic testing and economic constraints were highlighted as major concerns in the MEA. As the therapeutic landscape continues to expand, treatment selection for mCRPC needs to be increasingly personalized. Enhanced genetic testing and judicious utilization of newer therapies like olaparib, articulated by reimbursement support, should be made accessible for the underserved populations in the MEA. Increasing awareness on testing through educational activities catalyzed by digital technologies can play a central role in overcoming barriers to patient care in the MEA region. The involvement of multidisciplinary teams can bridge the treatment gaps, facilitating holistic and optimal management of mCRPC. Region-specific guidelines can help health-care workers navigate challenges and deliver personalized management through collaborative efforts – thus curb health-care variations and drive consistency. Development of region-specific scalable guidelines for genetic testing and treatment of mCRPC, factoring in the trade-off for access, availability, and affordability, is crucial. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

28. ABO Blood Group Alleles and Prostate Cancer Risk: Results from the Breast and Prostate Cancer Cohort Consortium (BPC3)

Author

Markt, Sarah C., Shui, Irene M., Unger, Robert H., Urun, Yuksel, Berg, Christine D., Black, Amanda, Brennan, Paul, Bueno-de-Mesquita, Bas H., Gapstur, Susan M., Giovannucci, Edward, Haiman, Christopher, Henderson, Brian, Hoover, Robert N., Hunter, David J., Key, Timothy J., Khaw, Kay-Tee, Canzian, Federico, Larranga, Nerea, Le Marchand, Loic, Ma, Jing, Naccarati, Alessio, Siddiq, Afshan, Stampfer, Meir J., Stattin, Par, Stevens, Victoria L., Stram, Daniel O., Tjnneland, Anne, Travis, Ruth C., Trichopoulos, Dimitrios, Ziegler, Regina G., Lindstrom, Sara, Kraft, Peter, Mucci, Lorelei A., Choueiri, Toni K., and Wilson, Kathryn M.

Published
2015
Full Text
View/download PDF

30. Predictive Factor for Lymph Node Metastasis in Non-Metastatic Colorectal Adenocarcinomas.

Author

Karci, Ebru, Urun, Yuksel, Koksoy, Elif B., Ucar, Gokhan, Bilgin, Burak, Yekeduz, Emre, Arslan, Cagatay, Alkan, Ali, Dede, Isa, Tuncay, Gulseren, Hocazade, Cemil, Ozdemir, Nuriye Yildirim, Sendur, Mehmet A. N., Utkan, Gungor, Yalcin, Bulent, and Akbulut, Hakan

Subjects
RISK of metastasis, ADENOCARCINOMA, CANCER invasiveness, LYMPH nodes, COLORECTAL cancer, RISK assessment, CANCER patients, TUMOR grading
Abstract

Objectives: To evaluate the predictive factors of lymph node involvement in non-metastatic colorectal adenocarcinomas (nmCRC). Methods: A total of 453 patients diagnosed with nmCRC were analyzed regarding T stage, lymphovascular invasion status, tumor grade and proposed risk score (RS), determined by the combination of these three factors for lymph node metastasis. Results: The median age was 62 (25-90 years), M/F ratio was 1.4:1 and majority of the patients had tumors localized on the left colon (70.6%). The number of excised lymph nodes was ≥12 in 77% of the cases. The postoperative pathological assessments revealed that 57.2% of patie,nts had N0 disease, 29.1% had N1 disease, and 13.7% had N2 disease. The T stages (p=0.007), grade (p<0.001), lymphovascular invasion (p=0.002), RS (p<0.001), and number of excised lymph nodes (p=0.029) were significantly different between N0, N1, and N2 patients. Higher RS was associated with lymph node metastasis (p<0.001). Conclusion: The risk score may predict lymph node metastasis in patients with nmCRC and if validated may be helpful in the decision-making of adjuvant chemotherapy, especially in the elderly and patients with inadequate lymph node dissection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

31. Hematology and Oncology

Author

Shulman, Lawrence, primary, LaCasce, Ann, additional, Chen, Wendy Y., additional, Urun, Yuksel, additional, Choueiri, Toni K., additional, Connors, Jean M., additional, Enzinger, Peter, additional, Berliner, Nancy, additional, Okam, Maureen M., additional, Pomerantz, Mark M., additional, Jackman, David M., additional, Glotzbecker, Brett E., additional, Alyea, Edwin P., additional, DeAngelo, Daniel J., additional, Handin, Robert I., additional, Meyerhardt, Jeffrey A., additional, and Woodmansee, Whitney W., additional

Published
2014
Full Text
View/download PDF

34. Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.

Author

Matsubara, Nobuaki, primary, De Bono, Johann S., additional, Olmos, David, additional, Procopio, Giuseppe, additional, Kawakami, Satoru, additional, Urun, Yuksel, additional, van Alphen, Robbert J., additional, Flechon, Aude, additional, Carducci, Michael Anthony, additional, Choi, Young Deuk, additional, Hotte, Sebastien J., additional, Korbenfeld, Ernesto Pablo, additional, Kramer, Gero, additional, Agarwal, Neeraj, additional, Dearden, Simon, additional, Gresty, Christopher, additional, Kang, Jinyu, additional, Poehlein, Christian Heinrich, additional, Harrington, Elizabeth, additional, and Hussain, Maha H. A., additional

Published
2021
Full Text
View/download PDF

36. Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation

Author

Erturk, Ismail, primary, Karadurmus, Nuri, additional, Kızıloz, Halil, additional, Acar, Ramazan, additional, Yildiz, Birol, additional, Aykan, Musa Baris, additional, Esen, Ramazan, additional, Buyukturan, Galip, additional, Urun, Yuksel, additional, Erdem, Gokhan, additional, and Arpacı, Fikret, additional

Published
2020
Full Text
View/download PDF

40. Merkel cell carcinoma in Turkey: A multicentric study

Author

Yildiz, Fatih, primary, Demirci, Umut, additional, Küçükarda, Ahmet, additional, Büyüksimsek, Mahmut, additional, Sakalar, Teoman, additional, Topcu, TurkanOzturk, additional, Aslan, Ferit, additional, Tufan, Gulnihal, additional, Aydin, Ovgu, additional, Turna, Hande, additional, Babacan, NalanAkgul, additional, Basoglu, Tugba, additional, Kurt, Bediz, additional, Yildiz, Birol, additional, Eren, Tülay, additional, Demiray, AtikeGokcen, additional, Gumusay, Ozge, additional, Arslan, Cagatay, additional, Özdemir, Nuriye, additional, Urun, Yuksel, additional, Baykara, Meltem, additional, Turan, Nedim, additional, Uysal, Mukremin, additional, Bilici, Ahmet, additional, Kavgaci, Halil, additional, Çiçin, İrfan, additional, Kilickap, Saadettin, additional, and Paydas, Semra, additional

Published
2020
Full Text
View/download PDF

41. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Petrylak, Daniel P, primary, de Wit, Ronald, additional, Chi, Kim N, additional, Drakaki, Alexandra, additional, Sternberg, Cora N, additional, Nishiyama, Hiroyuki, additional, Castellano, Daniel, additional, Hussain, Syed A, additional, Fléchon, Aude, additional, Bamias, Aristotelis, additional, Yu, Evan Y, additional, van der Heijden, Michiel S, additional, Matsubara, Nobuaki, additional, Alekseev, Boris, additional, Necchi, Andrea, additional, Géczi, Lajos, additional, Ou, Yen-Chuan, additional, Coskun, Hasan Senol, additional, Su, Wen-Pin, additional, Bedke, Jens, additional, Gakis, Georgios, additional, Percent, Ivor J, additional, Lee, Jae-Lyun, additional, Tucci, Marcello, additional, Semenov, Andrey, additional, Laestadius, Fredrik, additional, Peer, Avivit, additional, Tortora, Giampaolo, additional, Safina, Sufia, additional, Garcia del Muro, Xavier, additional, Rodriguez-Vida, Alejo, additional, Cicin, Irfan, additional, Harputluoglu, Hakan, additional, Tagawa, Scott T, additional, Vaishampayan, Ulka, additional, Aragon-Ching, Jeanny B, additional, Hamid, Oday, additional, Liepa, Astra M, additional, Wijayawardana, Sameera, additional, Russo, Francesca, additional, Walgren, Richard A, additional, Zimmermann, Annamaria H, additional, Hozak, Rebecca R, additional, Bell-McGuinn, Katherine M, additional, Powles, Thomas, additional, Wong, Suet-Lai Shirley, additional, Tan, Thean Hsiang, additional, Hovey, Elizabeth Jane, additional, Clay, Timothy Dudley, additional, Wan Ng, Siobhan Su, additional, Rutten, Annemie, additional, Machiels, Jean-Pascal, additional, Dumez, Herlinde, additional, Cheng, Susanna Yee-Shan, additional, Ferrario, Cristiano, additional, Sengeloev, Lisa, additional, Jensen, Niels Viggo, additional, Thibault, Constance, additional, Laguerre, Brigitte, additional, Joly, Florence, additional, Culine, Stéphane, additional, Becht, Catherine, additional, Niegisch, Günter, additional, Stöckle, Michael, additional, Grimm, Marc-Oliver, additional, Schwentner, Christina A, additional, Schultze-Seemann, Wolfgang, additional, Kalofonos, Haralambos, additional, Mavroudis, Dimitrios, additional, Papandreou, Christos, additional, Karavasilis, Vasilis, additional, Révész, Janos, additional, Rosenbaum, Eli, additional, Leibowitz-Amit, Raya, additional, Kejzman, Daniel, additional, Sarid, David, additional, Scagliotti, Giorgio Vittorio, additional, Bracarda, Sergio, additional, Massari, Francesco, additional, Osawa, Takahiro, additional, Miyajima, Naoto, additional, Shinohara, Nobuo, additional, Fukuta, Fumimasa, additional, Ohyama, Chikara, additional, Obara, Wataru, additional, Yamashita, Shinichi, additional, Tomita, Yoshihiko, additional, Kawai, Koji, additional, Fukasawa, Satoshi, additional, Oyama, Masafumi, additional, Yonese, Junji, additional, Nagata, Masayoshi, additional, Uemura, Motohide, additional, Nishimura, Kazuo, additional, Kawakita, Mutsushi, additional, Tsunemori, Hiroyuki, additional, Hashine, Katsuyoshi, additional, Inokuchi, Junichi, additional, Yokomizo, Akira, additional, Nagamori, Satoshi, additional, Lee, Hyo Jin, additional, Park, Se Hoon, additional, Rha, Sun Young, additional, Kim, Yu Jung, additional, Lee, Yun-Gyoo, additional, Vazquez Cortés, Leticia, additional, Lorena Urzua Flores, Claudia, additional, Blaisse, Reinoud J.B., additional, Erdkamp, Fransiscus L.G., additional, Aarts, Maureen J.B., additional, Wojcik-Tomaszewska, Joanna, additional, Tomczak, Piotr, additional, Sikora-Kupis, Bozena, additional, Schenker, Michael, additional, Herzal, Alina Amalia, additional, Udrea, Anghel Adrian, additional, Karlov, Petr, additional, Fomkin, Roman, additional, Gajate Borau, Pablo, additional, Grande, Enrique, additional, Delgado Mignorance, Juan Ignacio, additional, Su, Yu-Li, additional, Li, Jian-Ri, additional, Lin, Chien-Liang, additional, Lin, Chia-Chi, additional, Yeh, Su-Peng, additional, Erman, Mustafa, additional, Urun, Yuksel, additional, Golovko, Yuriy, additional, Bondarenko, Igor, additional, Sinielnikov, Ivan, additional, Crabb, Simon J., additional, Syndikus, Isabel, additional, Huddart, Robert, additional, Sundar, Santhanam, additional, Chowdhury, Simon, additional, Sarwar, Naveed, additional, Flaig, Thomas W., additional, Pan, Chong Xian, additional, Schwarz, James K., additional, Cultrera, Jennifer Lyn, additional, Acs, Peter Istvan, additional, Hainsworth, John D., additional, Herms, Benjamin T., additional, Lawler, William Eyre, additional, and Lowe, Thomas Eugene, additional

Published
2020
Full Text
View/download PDF

42. Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation.

Author

Erturk, Ismail, Karadurmus, Nuri, Kızıloz, Halil, Acar, Ramazan, Yildiz, Birol, Aykan, Musa Baris, Esen, Ramazan, Buyukturan, Galip, Urun, Yuksel, Erdem, Gokhan, and Arpacı, Fikret

Subjects
GERMINOMA, ETOPOSIDE, SURVIVAL, CARBOPLATIN, CONFIDENCE intervals, CANCER chemotherapy, METASTASIS, RETROSPECTIVE studies, CANCER patients, DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation
Abstract

Introduction and aim: To demonstrate the real-life data about patients who underwent AHSCT due to GCT. Methods: Between November 2016 and April 2020, 64 patients who received CE as high-dose chemotherapy for AHSCT in the Gulhane Education and Research Hospital were included in the study. Sixty-one patients received one AHSCT with CE chemotherapy regimen. Survival data and clinical characteristics were evaluated retrospectively. Results: The mean age of the patients were 31.9 ± 9 (min-max:18–55). With a median follow-up of 10.7 ± 8.7 months, the 1-year progression-free survival (PFS) rate was 57.8%, and the 1-year overall survival rate was 77.5%. Median overall survival (OS) and progression-free survival (PFS) times were 21.5 ± 1.8 (95% CI: 14.5–33.4) and 20 ± 2 months, respectively. The response rate was 72%. There were three treatment-related deaths. Conclusion: This sizeable single-centre study shows that patients with relapsed metastatic GCT are curable by CE as high dose chemotherapy plus AHSCT with reliable toxicity even for a single cycle. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. PD47-08 FIERCE-21: PHASE 2 STUDY OF VOFATMAB (B-701), A SELECTIVE INHIBITOR OF FGFR3, AS SALVAGE THERAPY IN METASTATIC UROTHELIAL CARCINOMA (MUCC)

Author

Graeme Currie, See Tong Pang, Ulka N. Vaishampayan, Sumanta K. Pal, Begoña Mellado, Daniel Castellano, Urun Yuksel, Steve Abella, Andrea Necchi, and Se Hoon Park

Subjects
Poor prognosis, Chemotherapy, Metastatic Urothelial Carcinoma, business.industry, Urology, Immune checkpoint inhibitors, medicine.medical_treatment, 030232 urology & nephrology, Salvage therapy, Phases of clinical research, 03 medical and health sciences, 0302 clinical medicine, Cancer research, bacteria, Medicine, business
Abstract

INTRODUCTION AND OBJECTIVES:Patients (pts) with mUC who have failed platinum-based chemotherapy have a poor prognosis. About 20% of them usually respond to immune checkpoint inhibitors (ICI). Also,...

Published
2019

45. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study

Author

Arzu Yaşar, H, primary, Turna, Hande, additional, Esin, Ece, additional, Murat Sedef, A, additional, Alkan, Ali, additional, Oksuzoglu, Berna, additional, Ozdemir, Nuriye, additional, Sendur, MA Nahit, additional, Sezer, Ahmet, additional, Kılıckap, Saadettin, additional, Utkan, Gungor, additional, Akbulut, Hakan, additional, Celik, Ismail, additional, Abalı, Huseyin, additional, and Urun, Yuksel, additional

Published
2019
Full Text
View/download PDF

46. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study

Author

Urun, Yuksel, primary, Yasar, H Arzu, additional, Turna, Hande, additional, Esin, Ece, additional, Sedef, A Murat, additional, Alkan, Ali, additional, Oksuzoglu, Berna, additional, Ozdemir, Nuriye, additional, Sendur, MA Nahit, additional, Sezer, Ahmet, additional, Kılıckap, Saadettin, additional, Utkan, Gungor, additional, Akman, Tulay, additional, Akbulut, Hakan, additional, Celik, Ismail, additional, and Abalı, Huseyin, additional

Published
2018
Full Text
View/download PDF

47. Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study.

Author

Arzu Yaşar, H, Turna, Hande, Esin, Ece, Murat Sedef, A, Alkan, Ali, Oksuzoglu, Berna, Ozdemir, Nuriye, Sendur, MA Nahit, Sezer, Ahmet, Kılıckap, Saadettin, Utkan, Gungor, Akbulut, Hakan, Celik, Ismail, Abalı, Huseyin, and Urun, Yuksel

Subjects
MELANOMA prognosis, CONFIDENCE intervals, HEMOGLOBINS, LACTATE dehydrogenase, MEDICAL cooperation, MUCOUS membranes, GENETIC mutation, RESEARCH, STATISTICS, UVEA cancer, PROPORTIONAL hazards models, RETROSPECTIVE studies, DATA analysis software, IPILIMUMAB, KAPLAN-Meier estimator, LOG-rank test
Abstract

Objective: To evaluate prognostic factors associated with the use of ipilimumab in patients with mucosal and uveal melanoma. Methods: In this multicenter, retrospective study, 31 patients with uveal and mucosal melanoma diagnosed between 2010 and 2017 were enrolled. Patients' characteristics, metastatic disease sites, treatment before ipilimumab therapy, performance status, hemoglobin, lactate dehydrogenase levels, B-RAF and c-kit mutation status, toxicity, and survival data were assessed for patients with mucosal and uveal melanoma. SPSS version 17 was used for statistical analysis. Kaplan–Meier method was used for survival analysis. The log-rank test was used for univariate analyses. The Cox regression analysis was used to test the association between multivariate variables and survival. The p-value of less than 0.05 was considered statistically significant. Results: Twenty patients had uveal and eleven patients had mucosal melanoma. The median overall survival was seven months (95% confidence interval: 1.1–12.7). In univariate analysis, while bone metastasis, anemia, high lactate dehydrogenase level, and more metastatic sites were associated with lower overall survival, better treatment response and administration of ipilimumab in first or second lines were associated with favorable overall survival. In multivariate analysis, only treatment response status and administration of ipilimumab in first or second lines were found to be significant as independent prognostic factors for survival. Conclusion: Ipilimumab therapy may be associated with increased survival, but this retrospective small N study makes that hard to definitely conclude. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.

Author

Urun, Yuksel, Yasar, H Arzu, Turna, Hande, Esin, Ece, Sedef, A Murat, Alkan, Ali, Oksuzoglu, Berna, Ozdemir, Nuriye, Sendur, MA Nahit, Sezer, Ahmet, Kılıckap, Saadettin, Utkan, Gungor, Akman, Tulay, Akbulut, Hakan, Celik, Ismail, and Abalı, Huseyin

Subjects
*MELANOMA prognosis, *BONE metastasis, *CANCER patient psychology, *MELANOMA, *METASTASIS, *NEUTROPHILS, *OXIDOREDUCTASES, *SURVIVAL analysis (Biometry), *TREATMENT effectiveness, *PROPORTIONAL hazards models, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *IPILIMUMAB, *KAPLAN-Meier estimator, *LYMPHOCYTE count, *LOG-rank test, *THERAPEUTICS
Abstract

Purpose: Studies in the last decade show survival improvement with checkpoint blocker therapy in patients with metastatic malign melanoma. Our purpose was to define the efficacy of ipilimumab according to the patient's baseline characteristics including absolute lymphocytes count. Methods: We collected the data of 97 patients with advanced malign melanoma treated with ipilimumab (3 mg/kg, q3w) retrospectively. Log-rank test was used to analyze the univariate effects of patient's characteristics (age, gender, metastatic sites, ECOG PS, type of melanoma, lactic dehydrogenase levels, anemia, lymphocytes (L), neutrophils (N), N/L ratio), c-kit and BRAF status. Survival analyses were estimated with Kaplan–Meier method. Cox regression analysis was used to assess the possible factors identified with log-rank test. Results: The median age was 58, and 58% were male and 90% of patients had at least one prior systemic therapy. The median survival was 9.7 months for all patients; and the 12- and 24-month survival rates were 43% and 19%, respectively. Absolute lymphocytes count, lactic dehydrogenase level, bone metastasis, the number of metastatic sites, and RECIST response were significantly related to survival. After Cox regression analysis, RECIST response (complete or partial response), absolute lymphocytes count (more than 1500/mm3) and the number of metastatic sites (less than three sites) remained as significant independent prognostic factors for longer survival. Conclusion: Ipilimumab improved survival of patients with metastatic malign melanoma. However, patients with fewer metastatic sites and higher absolute lymphocytes count have a significantly better benefit. To determine if these markers could be used to direct patient therapy, further validation analysis is needed. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

50. Merkel cell carcinoma in Turkey: A multicentric study.

Author

Yildiz, Fatih, primary, Büyüksimsek, Mahmut, additional, Sakalar, Teoman, additional, Aydin, Ovgu, additional, Turna, Hande, additional, Babacan, Nalan Akgul, additional, Yildiz, Birol, additional, Arslan, Cagatay, additional, Özdemir, Nuriye, additional, Urun, Yuksel, additional, Uysal, Mukremin, additional, Gumusay, Ozge, additional, Tufan, Gulnihal, additional, Aslan, Ferit, additional, Paydas, Semra, additional, and Demirci, Umut, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results